Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
WW International operates a subscription-based weight management and wellness platform, primarily serving North American consumers through digital apps, workshops, and nutritional product sales. The company is in severe financial distress with negative operating margins of -30%, declining revenue (-11.6% YoY), and subscriber attrition as it competes against GLP-1 weight loss drugs (Ozempic, Wegovy) and free fitness apps. The stock has collapsed -70% over the past year as the core business model faces existential disruption.
WW generates recurring revenue through monthly/annual subscriptions ($20-25/month range) for access to its proprietary Points system, digital tools, and community support. The business historically relied on high gross margins (68%) from software/content delivery with minimal variable costs, but customer acquisition costs have surged while lifetime value has collapsed due to pharmaceutical competition. Pricing power has eroded significantly as consumers shift to prescription GLP-1 medications or free alternatives like MyFitnessPal and Noom. The company lacks defensible intellectual property as its Points-based tracking system faces commoditization.
Monthly active subscriber counts and net subscriber additions/losses - the primary indicator of business viability
Average revenue per subscriber (ARPU) trends - reflects pricing power and product mix shifts between digital-only and premium tiers
Customer acquisition cost (CAC) and churn rates - deteriorating unit economics signal structural decline
Competitive developments in GLP-1 drug accessibility (insurance coverage expansion, pricing, supply constraints)
Strategic pivot announcements or partnership deals (e.g., integration with healthcare providers, pharmacy benefits managers)
Liquidity events and debt covenant compliance given the distressed balance sheet
Pharmaceutical disruption from GLP-1 agonists (semaglutide, tirzepatide) which deliver superior weight loss outcomes (15-20% body weight vs 5-8% for behavioral programs), creating permanent market share loss as insurance coverage expands and costs decline
Commoditization of digital weight tracking as free/low-cost apps replicate core functionality without proprietary barriers, and AI-powered personalized nutrition apps emerge
Secular shift toward medical weight management supervised by healthcare providers rather than consumer self-directed programs
Direct competition from Noom (behavioral psychology approach with lower pricing), MyFitnessPal (free calorie tracking), and emerging telehealth weight loss platforms that bundle GLP-1 prescriptions with coaching
Retail/pharmacy competition as CVS, Walgreens, and Amazon expand into weight management services with integrated product sales and prescription fulfillment
Celebrity/influencer-backed wellness brands with stronger social media engagement and younger demographic appeal
Going concern risk - negative operating cash flow of approximately $0M (near-zero) with minimal cash generation capacity and high fixed costs creates existential liquidity threat within 12-18 months without restructuring
Debt covenant compliance risk with 1.45x Debt/Equity ratio and deteriorating EBITDA potentially triggering technical defaults or requiring expensive amendments
Negative equity value implied by -272.6% ROE suggests book value destruction and potential balance sheet insolvency if asset impairments are recognized
high - Weight management subscriptions are discretionary consumer spending that correlates strongly with disposable income and consumer confidence. During recessions, consumers cancel non-essential subscriptions first. The $20-25/month price point competes with streaming services, gym memberships, and other wellness spending. However, the current distress is structural (pharmaceutical disruption) rather than cyclical, so macro improvements may not restore growth.
Rising interest rates increase the company's debt servicing costs (Debt/Equity of 1.45x) and compress valuation multiples for unprofitable growth companies. Higher rates also reduce consumer discretionary spending capacity through mortgage/credit card costs. The distressed valuation (0.3x P/S) suggests the market is pricing in bankruptcy risk, making cost of capital considerations secondary to survival concerns.
Critical - The company's negative cash flow and operating losses make access to credit markets essential for survival. Tightening credit conditions or covenant breaches could trigger restructuring. The business requires ongoing liquidity to fund operations and potential strategic pivots.
distressed/special situations - The stock trades at 0.3x sales with -70% one-year return, attracting deep value investors betting on restructuring, turnaround, or liquidation value. Not suitable for traditional growth, income, or momentum investors given negative cash flow and declining fundamentals. Highly speculative with binary outcomes (successful pivot vs bankruptcy).
high - The stock exhibits extreme volatility with -69.9% one-year return and -30.5% six-month return. Small market cap ($0.2B) and distressed fundamentals create susceptibility to sharp moves on any news regarding subscriber trends, financing, or competitive developments. Options market likely prices high implied volatility.
